RayKnowChina Research Map
Shortlist0

Not yet recruitingStomach cancerPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Nanfang Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorNanfang Hospital南方医科大学南方医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07603349, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Cohort 1: TRG grade 3 and postoperative pathological stage ypT3-4N2-3M0.

    Inclusion criterion 7

    Cohort 2: TRG grade 0 and postoperative pathological stage ypT0N0M0.

    Inclusion criterion 8

  3. Female participants of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after the last dose of study treatment. Male participants with female partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the last dose of study treatment.

    Inclusion criterion 13

    Active tuberculosis within 1 year or previous anti-tuberculosis treatment.

    Exclusion criterion 12

    Female participants who are pregnant, breastfeeding, or planning to become pregnant during treatment or within 6 months after the end of treatment.

    Exclusion criterion 13

  4. ECOG performance status of 0 or 1.

    Inclusion criterion 9

  5. Underwent any surgery requiring general anesthesia that was not related to gastric cancer within 28 days before randomization.

    Exclusion criterion 5

    History of or current diagnosis of another malignancy within 5 years.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07603349, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key Inclusion Criteria:

  • Voluntarily signed written informed consent.
  • Aged 18 to 75 years, inclusive, regardless of sex.
  • Underwent radical gastrectomy with D2 or more extended lymphadenectomy and achieved R0 resection. Surgical approaches may include open or laparoscopic surgery.
  • Histopathologically confirmed gastric or gastroesophageal junction adenocarcinoma.
  • Received preoperative neoadjuvant immunotherapy combined with chemotherapy, including oxaliplatin plus fluoropyrimidine-based chemotherapy. Immunotherapy may include anti-PD-1 monoclonal antibodies, anti-PD-L1 monoclonal antibodies, PD-1/CTLA-4 bispecific antibodies, and other immune checkpoint inhibitors.
  • Eligible for one of the following predefined cohorts:
  • Cohort 1: TRG grade 3 and postoperative pathological stage ypT3-4N2-3M0.
  • Cohort 2: TRG grade 0 and postoperative pathological stage ypT0N0M0.
  • ECOG performance status of 0 or 1.
  • No evidence of metastasis or recurrence on postoperative imaging before enrollment.
  • Adequate organ function, defined as hematologic, hepatic, renal, and thyroid function meeting the protocol-specified criteria based on laboratory tests performed within 14 days before randomization.
  • Willing and able to comply with the study treatment, scheduled visits, laboratory tests, and other study procedures.
  • Female participants of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after the last dose of study treatment. Male participants with female partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the last dose of study treatment.

Key Exclusion Criteria:

  • Presence of liver, peritoneal, or other distant metastases.
  • Inability to take oral medications.
  • Unresolved postoperative complications at the time of randomization, such as postoperative infection, anastomotic leakage or wound dehiscence, gastrointestinal bleeding, pancreatic fistula, or intestinal obstruction.
  • Uncontrolled pericardial effusion, uncontrolled pleural effusion, or clinically significant moderate or greater ascites at screening, defined as any of the following: pleural effusion or ascites with clinical symptoms and detectable by physical examination; or pleural effusion or ascites requiring drainage and/or intracavitary treatment during screening.
  • Underwent any surgery requiring general anesthesia that was not related to gastric cancer within 28 days before randomization.
  • History of or current diagnosis of another malignancy within 5 years.
  • Active or prior autoimmune disease that may relapse or require immunosuppressive treatment within 2 weeks or during the study period; or a history of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency disease; or a history of organ transplantation.
  • Participation in another clinical study, or any condition that may interfere with the interpretation of the study results.
  • Any other severe acute or chronic disease that, in the investigator's judgment, may increase the risk associated with study participation or study treatment.
  • Active or uncontrolled infection requiring systemic antibiotic therapy within 2 weeks before randomization or at the time of randomization.
  • Diagnosis of interstitial pneumonia, noninfectious pneumonitis, pulmonary fibrosis, or acute lung disease.
  • Active tuberculosis within 1 year or previous anti-tuberculosis treatment.
  • Female participants who are pregnant, breastfeeding, or planning to become pregnant during treatment or within 6 months after the end of treatment.
  • History of psychotropic drug abuse with inability to discontinue, or presence of a psychiatric disorder.
  • Patients considered unsuitable for participation in this study by the investigator.

Quoted from ClinicalTrials.gov, NCT07603349, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07603349, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07603349